Metraipolis › archive › dc_923eb205dd9f

Phase II trial with nivolumab and sorafenib in HCC identified enrichment of immunosuppressive monocytes in patients with Child-Pugh B liver dysfunction — Europe PMC PMID:41831609

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41831609
DOI
10.1016/j.jhepr.2026.101817
License (as archived)
solo-consultazione
Archived
2026-11-04T12:49:41.490Z
SHA-256 of the archived text
4176d439d0deb1deeae0eab80fa6394b795328ba5e0ba5bfd5c6878d957c6c74
Stable URL of this page
https://metraipolis.com/documento/dc_923eb205dd9f

How to cite

Phase II trial with nivolumab and sorafenib in HCC identified enrichment of immunosuppressive monocytes in patients with Child-Pugh B liver dysfunction — Europe PMC PMID:41831609 — Europe PMC (en), https://europepmc.org/article/MED/41831609 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_923eb205dd9f (Metraipolis archive dc_923eb205dd9f, sha256 4176d439d0deb1deeae0eab80fa6394b795328ba5e0ba5bfd5c6878d957c6c74)
BibTeX
@misc{dc923eb205dd9f,
  title = {Phase II trial with nivolumab and sorafenib in HCC identified enrichment of immunosuppressive monocytes in patients with Child-Pugh B liver dysfunction — Europe PMC PMID:41831609},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41831609},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_923eb205dd9f; sha256 4176d439d0deb1deeae0eab80fa6394b795328ba5e0ba5bfd5c6878d957c6c74},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41831609. Agents can read the archived copy with the MCP tool read_document.